247 related articles for article (PubMed ID: 32699227)
1. Functional lupus anticoagulant testing in a large retrospective cohort of thrombosis patients with direct oral anticoagulants.
Reda S; Brügelmann A; Müller J; Oldenburg J; Pötzsch B; Rühl H
Sci Rep; 2020 Jul; 10(1):12221. PubMed ID: 32699227
[TBL] [Abstract][Full Text] [Related]
2. The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants.
Ząbczyk M; Kopytek M; Natorska J; Undas A
Clin Chem Lab Med; 2019 Aug; 57(9):1374-1381. PubMed ID: 30763261
[TBL] [Abstract][Full Text] [Related]
3. Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negatives.
Favaloro EJ; Mohammed S; Curnow J; Pasalic L
Pathology; 2019 Apr; 51(3):292-300. PubMed ID: 30665674
[TBL] [Abstract][Full Text] [Related]
4. Lupus anticoagulant diagnosis in patients receiving direct oral FXa inhibitors at trough levels: A real-life study.
Gay J; Duchemin J; Imarazene M; Fontenay M; Jourdi G
Int J Lab Hematol; 2019 Dec; 41(6):738-744. PubMed ID: 31487115
[TBL] [Abstract][Full Text] [Related]
5. Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting.
Antovic A; Norberg EM; Berndtsson M; Rasmuson A; Malmström RE; Skeppholm M; Antovic J
Thromb Haemost; 2017 Aug; 117(9):1700-1704. PubMed ID: 28640321
[TBL] [Abstract][Full Text] [Related]
6. Lupus-anticoagulant testing at NOAC trough levels.
Ratzinger F; Lang M; Belik S; Jilma-Stohlawetz P; Schmetterer KG; Haslacher H; Perkmann T; Quehenberger P
Thromb Haemost; 2016 Aug; 116(2):235-40. PubMed ID: 27075441
[TBL] [Abstract][Full Text] [Related]
7. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.
Testa S; Legnani C; Tripodi A; Paoletti O; Pengo V; Abbate R; Bassi L; Carraro P; Cini M; Paniccia R; Poli D; Palareti G
J Thromb Haemost; 2016 Nov; 14(11):2194-2201. PubMed ID: 27566988
[TBL] [Abstract][Full Text] [Related]
8. Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome.
Arachchillage DR; Mackie IJ; Efthymiou M; Isenberg DA; Machin SJ; Cohen H
J Thromb Haemost; 2015 Jul; 13(7):1264-73. PubMed ID: 25850997
[TBL] [Abstract][Full Text] [Related]
9. Performance Characteristics of DOAC-Remove for Neutralization of the Effects of Apixaban and Rivaroxaban in Lupus Anticoagulant Assays.
Skaugen JM; Sayre C; Hassett AC; Chibisov I; Bontempo F; Meyer MP; Seheult JN
Am J Clin Pathol; 2022 Mar; 157(3):457-469. PubMed ID: 34698336
[TBL] [Abstract][Full Text] [Related]
10. Detection of lupus anticoagulant in the era of direct oral anticoagulants.
Hoxha A; Banzato A; Ruffatti A; Pengo V
Autoimmun Rev; 2017 Feb; 16(2):173-178. PubMed ID: 27988438
[TBL] [Abstract][Full Text] [Related]
11. Potential usefulness of activated charcoal (DOAC remove®) for dRVVT testing in patients receiving Direct Oral AntiCoagulants.
Jourdi G; Delrue M; Stepanian A; Valaize J; Foulon-Pinto G; Demagny J; Duchemin J; Nedelec-Gac F; Darnige L; Curis E; Delavenne X; Gaussem P; Siguret V; Gouin-Thibault I
Thromb Res; 2019 Dec; 184():86-91. PubMed ID: 31710863
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
Gosselin R; Grant RP; Adcock DM
Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
[TBL] [Abstract][Full Text] [Related]
13. Interference of DOACs in different DRVVT assays for diagnosis of lupus anticoagulants.
Flieder T; Weiser M; Eller T; Dittrich M; von Bargen K; Alban S; Kuhn J; Knabbe C; Birschmann I
Thromb Res; 2018 May; 165():101-106. PubMed ID: 29627719
[TBL] [Abstract][Full Text] [Related]
14. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants.
Ebner M; Birschmann I; Peter A; Spencer C; Härtig F; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
Crit Care; 2017 Feb; 21(1):32. PubMed ID: 28196509
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of global laboratory methods and establishing on-therapy ranges for monitoring apixaban and rivaroxaban: Experience at a single institution.
Park SH; Seo YH; Park PW; Kim KH; Seo JY; Lee HT; Kwoun WJ; Ahn JY
J Clin Lab Anal; 2019 Jun; 33(5):e22869. PubMed ID: 30860622
[TBL] [Abstract][Full Text] [Related]
16. Screening test for direct oral anticoagulants with the dilute Russell viper venom time.
Pratt J; Crispin P
Eur J Haematol; 2018 Jun; 100(6):567-574. PubMed ID: 29486103
[TBL] [Abstract][Full Text] [Related]
17. Applying index of circulating anticoagulant to mixing tests with lupus anticoagulant screen and confirm reagents can distinguish with high specificity between lupus anticoagulants and direct factor Xa inhibitors.
Kumano O; Amiral J; Dunois C; Peyrafitte M; Moore GW
Int J Lab Hematol; 2021 Aug; 43(4):771-778. PubMed ID: 33974363
[TBL] [Abstract][Full Text] [Related]
18. Unveiling the complex effects of direct oral anticoagulants on dilute Russell's viper venom time assays.
Hillarp A; Strandberg K; Gustafsson KM; Lindahl TL
J Thromb Haemost; 2020 Aug; 18(8):1866-1873. PubMed ID: 32294291
[TBL] [Abstract][Full Text] [Related]
19. Alternative assays to dRVVT and aPTT for lupus anticoagulant detection.
Moore GW
Am J Hematol; 2020 Aug; 95(8):992-998. PubMed ID: 32311119
[TBL] [Abstract][Full Text] [Related]
20. Impact of a commercially available DOAC absorbent on two integrated procedures for lupus anticoagulant detection.
Tripodi A; Scalambrino E; Chantarangkul V; Paoletti O; Clerici M; Novembrino C; Boscolo-Anzoletti M; Peyvandi F; Testa S
Thromb Res; 2021 Aug; 204():32-39. PubMed ID: 34126321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
